Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 Visninger
• 07/18/23
0
0
Indlejre
administrator
Abonnenter
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Vis mere
Facebook kommentarer
SORT BY-
Topkommentarer
-
Seneste kommentarer